Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | PDE4A | P27815 | 8/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 8/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 8/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395394 | 1.00 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL1892011 | 0.96 | ADORA2B (0.92) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL21381249 | 0.94 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11661797 | 0.94 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL4423680 | 0.91 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL13728725 | 0.86 | ADORA2A (0.75) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9845195 | 0.86 | ADORA2A (0.75) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL17748264 | 0.86 | ADORA2B (0.89) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL31081359 | 0.85 | ADORA2B (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5039468 | 0.85 | ADORA2B (0.74) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105073749-A | Improved process for the preparation of linagliptin | MYLAN LAB LTD | 2015-11-18 | — | — | CN | claimed |
| EP-2935266-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | Mylan Laboratories Ltd. (IN) | 2015-10-28 | — | — | EP | claimed |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2015-10-22 | — | — | US | claimed |
| WO-2014097314-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2014-06-26 | — | — | WO | claimed |
| US-5700369-A | Process for adsorboaggregational flotation of Carlin type natural gold ore dressing | GUANGZHOU INSTITUTE OF GEOCHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 1997-12-23 | — | — | US | claimed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | claimed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| CN-122029936-A | Light-emitting element, display device, and method for manufacturing light-emitting element | 夏普显示科技株式会社 | 2026-05-12 | — | — | CN | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
| CN-108588015-A | A kind of human mesenchymal stem cell adipogenic induction differential medium and preparation method | 安徽瑞杰赛尔生物科技有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-0944725-A1 | PHOSPHODIESTERASE 8A | ICOS CORPORATION (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5932465-A | POLYPEPTIDE FOR DETECTING ALLELIC VARIANTS; DEVELOPING ANTISENSE AGENTS; GENETIC PROBES; DEVELOPING THERAPEUTIC MODELS | ICOS CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999019495-A1 | PHOSPHODIESTERASE 8A | ICOS CORPORATION (US) | 1999-04-22 | — | — | WO | disclosed |
| US-5700369-A | Process for adsorboaggregational flotation of Carlin type natural gold ore dressing | GUANGZHOU INSTITUTE OF GEOCHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 1997-12-23 | — | — | US | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| US-4289776-A | VASODILATORS, FIBRINOLYTIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-09-15 | — | — | US | disclosed |
| US-4242345-A | VASODILATORS | Wulfing, Johann A. (DE) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | ADORA2B 3323/4885ADORA2A 3171/4885PDE4A 1873/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | ADORA2B 3323/4885ADORA2A 3171/4885PDE4A 1873/4885 |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP3, DPP8 | ADORA2B 1759/4885ADORA2A 2758/4885PDE4A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.